Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1111/bjh.14490 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Chemotherapy-free approach with arsenic trioxide and retinoic acid in children with acute promyelocytic leukemia.
Leuk Lymphoma
December 2024
Division of Pediatric Hematology-Oncology, First Department of Pediatrics, "Aghia Sophia" Children's Hospital, National and Kapodistrian University of Athens, Athens, Greece.
Second trimester medical abortion in acute promyelocytic leukaemia.
BMJ Case Rep
December 2024
Haematology, Post Graduate Institute of Medical Education and Research, Chandigarh, India.
Acute promyelocytic leukaemia (APL) is a highly lethal haematological malignancy. It is rare in pregnancy and may be fatal if not managed promptly and appropriately. A woman in her 20s presented with high-grade fever at 16 weeks of her third pregnancy.
View Article and Find Full Text PDFStudy on clinical features of early death in older patients with acute promyelocytic leukemia.
Ann Hematol
December 2024
Key Laboratory of Hepatosplenic Surgery, Ministry of Education, The First Affiliated Hospital of Harbin Medical University, Harbin, 150001, People's Republic of China.
This study aimed to analyze the baseline clinical characteristics, as well as the clinical features and risk factors of early death (ED) in older patients with acute promyelocytic leukemia (APL). A retrospective analysis was conducted on 198 consecutive older patients (age ≥ 50 years) with newly diagnosed APL who received arsenic trioxide alone as induction therapy, with 354 younger patients (age < 50 years) as controls. Ten easily obtainable clinical parameters were selected.
View Article and Find Full Text PDFA distinct subgroup of AML resembling the APL immunophenotype is associated with DIC.
BMC Cancer
December 2024
Department of Hematology, Zhongnan Hospital of Wuhan University, Wuhan, 430071, China.
Background: The complexity of acute myeloid leukemia (AML) is increasingly recognized through the identification of distinct subgroups, including those with an APL-like immunophenotype characterized by the absence of CD34 and HLA-DR expression, which is widely recognized as a representative immunophenotype in acute promyelocytic leukemia (APL). This study sought to understand the clinical, molecular, and prognostic differences between AML patients with and without this phenotype.
Methods: This study retrospectively analysed 191 de novo non-M3 AML patients and identified 32 patients with the CD34HLA-DR phenotype resembling APL-like immunophenotype, considered as the experimental group.
Correction: JSH practical guidelines for hematological malignancies, 2023: leukemia-2-acute promyelocytic leukemia (APL).
Int J Hematol
December 2024
Department of Hematology, Saiseikai Yokohama Nanbu Hospital, 3-2-10 Konandai, Konan-ku, Yokohama, Kanagawa, 234-0054, Japan.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!